
|Videos|January 10, 2018
How to Improve Adjuvant Therapy in HER2-Positive Breast Cancer
Author(s)Ruth M. O'Regan, MD
This video reviews various trials that aimed to improve outcomes or minimize toxicities among patients receiving adjuvant treatment for HER2-positive breast cancer.
Advertisement
In this video, Ruth M. O’Regan, MD, of the University of Wisconsin, reviews various trials that aimed to improve outcomes or minimize toxicities among patients receiving adjuvant treatment for HER2-positive breast cancer.
O’Regan gave a presentation on this topic during an education session at the 2017 San Antonio Breast Cancer Symposium (SABCS).
Newsletter
Stay up to date on recent advances in the multidisciplinary approach to cancer.
Advertisement
Latest CME
Advertisement
Advertisement
Trending on CancerNetwork
1
Modifiable Risk Factors Suggest Potential for Improving Cancer Prevention
2
2026 Tandem Meetings: What’s the Latest Research in Multiple Myeloma?
3
Barriers to CAR T-Cell Referral and Center Access in Multiple Myeloma
4
Dato-DXd Receives Priority Review in Unresectable/Metastatic TNBC
5



































